- Non-high-density lipoprotein cholesterol (HDL-C) is linked to long-term cardiovascular disease (CVD) risk, according to the authors of this multinational study.
Why this matters
- These authors offer a “simple” tool that uses non-HDL-C for assessing risk and evaluates possible benefits of starting lipid-reducing therapy.
- With increasing serum non-HDL-C, 30-year CVD rates increased:
- 7.7% with
- 12.8% with
- Steepest risk increases seen in those under age 45 years at baseline.
- They found that reducing non-HDL-C by 50% decreased CVD event risk by age 75 years, with increasing benefit with earlier reductions.
- Data from the Multinational Cardiovascular Risk Consortium, 19 countries in Europe, Australia, and North America.
- 398,846 participants from 38 cohorts; of these, 199,415 were in the derivation cohort and 199,431 were used for validation.
- Funding: EU Framework Programme, others.
- Only baseline lipid values used.
- Most participants were of European ancestry.